William E. Cohn - 27 Apr 2023 Form 4 Insider Report for Cardiovascular Systems Inc

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 27 Apr 2023
Net transaction value: -$188,980
SEC form: 4
Accepted by SEC: 27 Apr 2023, 16:33:46 UTC
Prior SEC filing: 09 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Andrew Nick as Attorney-in-Fact for William E. Cohn pursuant to Power of Attorney previously filed.

Key filing fact

William E. Cohn filed Form 4 for Cardiovascular Systems Inc on 27 Apr 2023.

Key facts

This page summarizes William E. Cohn's Form 4 filing for Cardiovascular Systems Inc.
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Apr 2023, 16:33.

Change

Previous filing in this sequence was filed on 09 Aug 2022.
Current net transaction value: -$188,980.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CSII transaction

Common Stock

Disposed to Issuer

Transaction value: $188,980
Shares: -9,449
Change %: -100%
Price: $20.00
Shares after: 0
Date: 27 Apr 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CSII transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value: $0
Shares: -40,553
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Apr 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,553
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

William E. Cohn is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger by and among Cardiovascular Systems, Inc., a Delaware corporation, Abbott Laboratories, an Illinois corporation, and Cobra Acquisition Co., a Delaware corporation (the "Merger Agreement"), each share of common stock converted pursuant to the Merger Agreement into the right to receive $20.00 in cash per share, without interest and less any required withholding taxes.

Footnote F2

Pursuant to the Merger Agreement, each unvested restricted stock unit became fully vested immediately prior to the effective time of the merger. Restricted stock units were then cancelled as of the effective time of the merger in exchange for the right to receive a cash payment equal to $20.00 multiplied by the number of restricted stock units, without interest and less any required withholding of taxes.